Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04927702 · ClinicalTrials.gov registry record · NA

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

A NA study, sponsored by Acera Surgical.

Terminated
Registry status
NA
Development phase
48
Enrollment target

NCT04927702 is a NA study that was terminated before completion, run by Acera Surgical. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04927702, a NA study, was terminated before completion, sponsored by Acera Surgical.

TERMINATED
Registry status
NA
Development phase
48 participants
Enrollment target

Study Summary

In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)

Interventions

  • DEVICE Standard of Care
  • DEVICE Synthetic Hybrid-Scale Fiber Matrix
  • DEVICE Living Cellular Skin Substitute

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2021-07-19
Est. Completion 2024-08-01
Phase NA

Sponsor

Acera Surgical

5 total trials

What the Registry Record Tells You About NCT04927702

The ClinicalTrials.gov registry entry for NCT04927702 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acera Surgical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.

NCT04927702 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04927702 about?

NCT04927702 is a clinical study titled "Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)". In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hyb...

What is the current status of trial NCT04927702?

This trial is currently terminated. It is a NA study. The enrollment target is 48 participants. The study started on 2021-07-19. Estimated completion is 2024-08-01.

What interventions are being tested in trial NCT04927702?

The interventions under investigation include: Standard of Care (DEVICE), Synthetic Hybrid-Scale Fiber Matrix (DEVICE), Living Cellular Skin Substitute (DEVICE).

Who is sponsoring clinical trial NCT04927702?

This trial is sponsored by Acera Surgical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.